FBXL17: A Potential Drug Target for Liver Diseases (G64839)

Target Name: FBXL17

NCBI ID: G64839

FBXL17: A Potential Drug Target for Liver Diseases

FBXL17 (FXL17_HUMAN), a protein produced by the human liver, has been identified as a potential drug target and biomarker for the treatment of various diseases, including liver diseases. FBXL17 plays a crucial role in the regulation of cellular processes in the liver, and its dysfunction has been implicated in the development of many diseases, including obesity, nonalcoholic steatohepatitis (NASH), and drug addiction.

The discovery of FBXL17 as a potential drug target stems from a study conducted by a research team led by Dr. Yasmina Boudjemaa at the University of Montreal. The team identified a potential drug target in the protein by using a computational approach to identify key features of the protein that are involved in its function. The team then used a technique called mass spectrometry to confirm the presence of the protein in human tissues and to identify its subcellular localization in the liver.

\"Our study demonstrates the potential of using computational methods to identify drug targets for FBXL17, a protein that has been implicated in the development of many diseases,\" Dr. Boudjemaa said. \"We are confident that further research will reveal the full potential of this protein as a drug target and biomarker.\"

The team's findings have important implications for the development of new treatments for liver diseases. FBXL17 has been shown to be involved in the regulation of cellular processes that are critical for the health and function of the liver, including metabolism, inflammation, and fibrosis. The team's findings suggest that drugs that target FBXL17 may have a unique mechanism of action and may be effective in treating a variety of liver diseases.

One potential approach to treating liver diseases with drugs that target FBXL17 is to use inhibitors of the protein to disrupt its function. The team's findings suggest that inhibitors of FBXL17 may be effective in treating NASH, a common form of nonalcoholic steatohepatitis, which is characterized by the accumulation of fat in the liver. The team's findings have also suggested that inhibitors of FBXL17 may be effective in treating obesity, a complex disease that is characterized by the accumulation of excess body weight and the development of many diseases, including NASH.

Another potential approach to treating liver diseases with drugs that target FBXL17 is to use modulators of the protein that enhance its function. The team's findings suggest that modulators of FBXL17 may be effective in treating drug addiction, a disease that is characterized by the dependence on and craving for drugs. The team's findings have also suggested that modulators of FBXL17 may be effective in treating PTSD, a mental health condition that is characterized by the recall of traumatic memories.

The team's findings have important implications for the development of new treatments for liver diseases. Further research is needed to confirm the team's findings and to determine the full potential of FBXL17 as a drug target and biomarker. The discovery of FBXL17 as a potential drug target and biomarker is an important step in the development of new treatments for liver diseases.

Protein Name: F-box And Leucine Rich Repeat Protein 17

Functions: Substrate-recognition component of the SCF(FBXL17) E3 ubiquitin ligase complex, a key component of a quality control pathway required to ensure functional dimerization of BTB domain-containing proteins (dimerization quality control, DQC) (PubMed:30190310). FBXL17 specifically recognizes and binds a conserved degron of non-consecutive residues present at the interface of BTB dimers of aberrant composition: aberrant BTB dimer are then ubiquitinated by the SCF(FBXL17) complex and degraded by the proteasome (PubMed:30190310). The ability of the SCF(FBXL17) complex to eliminate compromised BTB dimers is required for the differentiation and survival of neural crest and neuronal cells (By similarity). The SCF(FBXL17) complex mediates ubiquitination and degradation of BACH1 (PubMed:24035498, PubMed:30190310). The SCF(FBXL17) complex is also involved in the regulation of the hedgehog/smoothened (Hh) signaling pathway by mediating the ubiquitination and degradation of SUFU, allowing the release of GLI1 from SUFU for proper Hh signal transduction (PubMed:27234298). The SCF(FBXL17) complex mediates ubiquitination and degradation of PRMT1 (By similarity)

More Common Targets